Andrew Forrest doubles as therapeutic ecstasy biotech Emyria
ASX-listed biotech Emyria (ASX:EMD), which is developing psychotherapy treatments using MDMA (aka ecstasy) and psilocybin (aka magic mushrooms), has raised $2.5 million in equity offering backed by existing investor Andrew Forrest through the healthtech company. fund Tenmile, part of its private investment group, Tattarang. The $2.5 million placement was jointly [...]